09.08.15
Irvine, Calif.-based Lombard Medical Inc., a medical device company focused on endovascular aortic repair of abdominal aortic aneurysms, has named medical device executive and investor David Milne as its new board member.
Milne serves as a managing partner of Boston-based venture capital firm SV Life Sciences. He has more than 30 years of operating, business development and venture capital experience in the medical device industry. Milne has held leadership positions in marketing, sales and business development, and has been involved in the founding of numerous medical technology companies.
Previously, he was chairman of the board of directors of Altura Medical, an endovascular stent graft developer acquired by Lombard in July this year. Milne currently sits on the board of a number of life science companies, including publicly traded Entellus and TransEnterix.
Before entering venture capital, Milne held various positions in the medical industry, including Vice President, Business Development for Boston Scientific where he was responsible for more than $2 billion of transactions with 30 companies, including acquisitions, mergers, equity and debt financing structures.
“Mr. Milne brings a tremendous wealth of global medical device experience and expertise to our Board,” said Raymond W. Cohen, chairman of the coard of Lombard. “His background is suited for contributing to the Company given his keen understanding of the endovascular stent graft market based on his work at Altura Medical.”
He has a Bachelor of Science degree in Biology from Rutgers University and an MBA in marketing/finance from New York University.
Milne serves as a managing partner of Boston-based venture capital firm SV Life Sciences. He has more than 30 years of operating, business development and venture capital experience in the medical device industry. Milne has held leadership positions in marketing, sales and business development, and has been involved in the founding of numerous medical technology companies.
Previously, he was chairman of the board of directors of Altura Medical, an endovascular stent graft developer acquired by Lombard in July this year. Milne currently sits on the board of a number of life science companies, including publicly traded Entellus and TransEnterix.
Before entering venture capital, Milne held various positions in the medical industry, including Vice President, Business Development for Boston Scientific where he was responsible for more than $2 billion of transactions with 30 companies, including acquisitions, mergers, equity and debt financing structures.
“Mr. Milne brings a tremendous wealth of global medical device experience and expertise to our Board,” said Raymond W. Cohen, chairman of the coard of Lombard. “His background is suited for contributing to the Company given his keen understanding of the endovascular stent graft market based on his work at Altura Medical.”
He has a Bachelor of Science degree in Biology from Rutgers University and an MBA in marketing/finance from New York University.